HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA sunscreen rule

This article was originally published in The Rose Sheet

Executive Summary

FDA is extending the comment period for its proposed sunscreen regulation to Dec. 26, 2007; the 90-day comment period initially was set to end Nov. 26. The proposed rule will amend the 1999 FDA final rule on sunscreens that block UVB rays to incorporate new testing and labeling requirements for products that protect against UVA rays (1"The Rose Sheet" Aug. 27, 2007, p. 3). The extension is in response to nine requests submitted to extend the comment period; eight of the requests were for an additional nine months in order to conduct laboratory testing and consumer studies on the proposed labeling system. "By extending the comment period for 30 days, FDA is balancing industry concerns and the interests of public health to ensure that sunscreen products properly inform customers of the level of protection they provide against UVA and UVB rays," the agency says Nov. 27...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS015105

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel